Format

Send to

Choose Destination
PLoS Biol. 2015 Jun 9;13(6):e1002165. doi: 10.1371/journal.pbio.1002165. eCollection 2015 Jun.

The Economics of Reproducibility in Preclinical Research.

Author information

1
Global Biological Standards Institute, Washington, D.C., United States of America.
2
Boston University School of Management, Boston, Massachusetts, United States of America.
3
Boston University School of Management, Boston, Massachusetts, United States of America; Council of Economic Advisers, Washington, D.C., United States of America.

Abstract

Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US$28,000,000,000 (US$28B)/year spent on preclinical research that is not reproducible-in the United States alone. We outline a framework for solutions and a plan for long-term improvements in reproducibility rates that will help to accelerate the discovery of life-saving therapies and cures.

Comment in

PMID:
26057340
PMCID:
PMC4461318
DOI:
10.1371/journal.pbio.1002165
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center